TY - JOUR T1 - Alpha-1 antitrypsin deficiency in COPD patients: Time to count it in! JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2020.2416 VL - 56 IS - suppl 64 SP - 2416 AU - Dilek Karadoğan AU - Songül Özyurt Y1 - 2020/09/07 UR - http://erj.ersjournals.com/content/56/suppl_64/2416.abstract N2 - Introduction: Alpha-1 antitrpsin (AAT) deficiency is considered as a situation that should be evaluated for all of COPD patients at least once in their lives at guidelines. Although this information is known at theoretical level, this rule is not followed in our country and in many other countries. The aim of this study was to evaluate the AAT serum levels of COPD patients and the detected genetic mutations.Methods: Study was planned after the visit of the researcher to the AATD reference center in Barcelona. The sample consisted of COPD patients who applied to two different health institutions. Comparison of patients characteristics was made according to examination status and levels of serum AAT, also detected mutations were evaluated.Results: Totally 135 COPD patients were evaluated. Mean age of the study population was 63.4±11.2, with male dominance (96.6%). Among them 54.8% of them were examined for serum AAT levels. The comparison of AAT level tested and non-tested groups showed that AAT level tested group’s mean age was lower (p<0.05). Among serum AAT level tested group, 87.8% of patients’ AAT level was between normal range of laboratory level while only 9 (12.1%) patients’ level was low. Comparison of groups with low and normal serum AAT levels showed that, mean FEV1/FVC and mean FEV1 levels of deficient group were lower (p<0.005). Among deficient 9 patients genetic mutation analysis confirmed 3 of them to have defect in Serpina 1 gene; 1 patient with Pi ZZ allele, 2 patients with Pi MZ allele. Patient with PiZZ allele is now under augmentation therapy for 3 months.Conclusion: Detection of COPD patients for AAT deficiency is feasible and relevant for future directions.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 2416.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -